A Practical Guide to Writing Risk Management Plans (RMPS)

Understand RMPs relationship to safety reviews; PBRERs/DSURs; licence submissions (CTD) and their maintenance

29 Jan 2018

& 4 Jul 2018

GBP 699
EUR 979
USD 1,090

Book now

Course Overview

Topics to be covered will include:-

  • An Introduction to ICH & EU RMPs – Production & Maintenance
  • Documentation to be Supplied to Regulatory Authorities – the process for RMPs
  • The EU Templates & their Completion – Generic and Innovator Products
  • RMPs in other Countries
  • Practical – Completion of Sections I – III
  • Practical – Completion of Sections IV – VI
  • Practical – Completion of Annexes

Why you should attend

The new Pharmacovigilance Legislation of 2012 now requires companies to provide Risk Management Plans (RMPs) and assessments for all new products whether those products are generic products or new chemical entities. If these are not done correctly this can delay both licensure and sales and damage the Company ability to maximise its products. Maintenance of the RMPs also is an important aspect for maintaining the licence, compliance and these are reviewed in Regulatory Inspections. Can you afford not to get this right?

Who should attend

This course will be relevant for anyone requiring a comprehensive overview of the Pharmacovigilance function and duties. It may be of particular interest to those who are responsible in Pharmacovigilance for any safety assessments and writing such plans including any Medical Directors who approve such plans. Those who work with pharmacovigilance, e.g. Regulatory Affairs, Clinical, Sales & Marketing, Legal, Commercial and Quality and EU QP PVs that must sign off such documents.

Programme

09.00 Registration and Coffee

09.30 Meeting begins

An Introduction to EU RMPs – Production & Maintenance

  • ICH E2E – Risk Management Plans
  • EU Module V – Risk Management Plans
  • Production of the EU RMP
  • Maintenance of the RMP (Safety Reviews; PSURs/DSURs)

Documentation to be Supplied to Regulatory Authorities – the process for RMPs

  • Generic RMPs
  • RMPs for Innovator products
  • Additional documents to supply to the Regulators
  • Safety reporting Timelines for RMPs
  • Japan and the USA and RMPs

The EU Templates & their Completion – Generic and Innovator Products Including RMPs in other Countries

  • The EU Generic template
  • The EU Template for innovator products
  • The RMP Template in Japan

Practical – Completion of Sections I – III

  • Section I – Information sources and completion
  • Section II – Common aspects for Risk appraisal from Clinical Studies
  • Section III – The Pharmacovigilance Plan

Practical – Completion of Sections IV – VI

  • Section IV – Post Authorisation Efficacy Studies
  • Section V – Risk Minimisation Activities
  • Section VI – Summary of the RMP

Practical – Completion of Annexes

  • Annex 1: Interface between RMP and Eudravigilance/EPITT
  • Annex 2: Summary of product characteristics (SmPC) and package leaflet.
  • Annex 3: Worldwide marketing authorisation status by country (including EEA)
  • Annex 4: Synopsis of on-going and completed clinical trial programme
  • Annex 5: Synopsis of on-going and completed pharmacoepidemiological study programme
  • Annex 6: Protocols for proposed and on-going studies
  • Annex 7: Specific adverse event follow-up forms
  • Annex 8: Protocols for proposed and on-going studies in RMP part IV
  • Annex 9: Synopsis of newly available study reports for RMP parts III-IV
  • Annex 10: Details of proposed additional risk minimisation activities (if applicable)
  • Annex 11: Mock up examples of the material provided to healthcare professionals and patients
  • Annex 12: Other supporting data (including referenced material)

17.00 Meeting ends

Presenter

Graeme Ladds (29 Jan 2018)

Graeme Ladds, Director of PharSafer, has over 26 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

Book now

29 Jan 2018
29 Jan 2018 Rembrandt Hotel, London GBP 699.00
EUR 979.00
USD 1,090.00
+ VAT @ 20.00%
Enrol now
4 Jul 2018
4 Jul 2018 Cavendish Hotel, London GBP 699.00
EUR 979.00
USD 1,090.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Alfa Wassermann S.p.A.
  • A Nelson & Co Ltd
  • Alfrapharma Srl
  • Cmed
  • Colgate-Palmolive R&D
  • Conforma NV
  • DBV Technologies
  • ELPEN Pharmaceutical Co Inc
  • Emtex BVBA
  • Ewopharma International s.r.o
  • FAES FARMA SA
  • Ferrer Internacional, S.A.
  • Iggea Ltd
  • IRE-TEX INNOVATIONS LTD
  • Jacobsen Pharma & MedTech Advice A/S
  • JensonR+ Ltd
  • Kem Pharmaceuticals Limited
  • Mapi Life Sciences Canada Inc.
  • Medac GmbH
  • Mediplex Ltd
  • NDA Regulatory Science Ltd
  • Norgine Ltd
  • Pharmacovigilance Matters Limited
  • ProductLife
  • Real Regulatory Ltd
  • Recordati
  • Red Line Pharmacovigilance
  • VAN Pharma Consult
  • Veterinary Medicines Directorate
  • ZAMBON SPA